Diabetomics Inc. Changes Name to Modality Dx Amid New Innovation and Expansion of Molecular Signature Diagnosis Products
PORTLAND, Ore.--(BUSINESS WIRE)--Diabetomics has been rebranded Modality Dx. Founded by Dr. Srinivasa Nagalla, Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes and autoimmune disease.
Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes and autoimmune disease.
Share
'Throughout my career, I've seen firsthand the great need for more preventive healthcare solutions,' said Dr. Nagalla. 'Too often doctors see patients after disease has already taken hold. My goal is to develop diagnostic tools that can assist in prevention and early intervention.'
Modality Dx has developed products that can identify molecular Signatures, provide rapid diagnostic testing, smart device technology and oral fluid technology.
Robert Gootee, Board Chair of Modality Dx, said, 'The goal of our research is to develop products that help healthcare professionals identify and treat disease early and accurately, thus enabling them to focus on effective disease prevention.'
Currently, Modality Dx holds patents for rapid test products that enable disease diagnosis in maternal health, diabetes and rheumatoid arthritis. These patented science and technology products enhance the measurement of treatment efficacy, thus improving the pharmaceutical industry's ability to identify precision targets that support drug development.
About Modality Dx
Modality Dx, a privately-held Oregon-based company founded in 2010, is focused on the rapid diagnosis of disease in the maternal health, diabetes and autoimmune sectors. Through science and business excellence, they are pioneering a quantitative precision-based approach to diseases diagnosis and treatment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
an hour ago
- Buzz Feed
Study Reveals The Biggest Risk Factors For Getting Early Dementia
Overall, the study results are consistent with what medical experts have been advising patients for years. Dr. Arman Fesharaki-Zadeh, an assistant professor of psychiatry and of neurology at the Yale School of Medicine, recommended three 'lifestyle measures' that folks may want to consider when trying to lower their risk of young-onset dementia ― starting with physical exercise. 'An active daily exercise practice can have far-reaching benefits, which include enhanced neurocognitive function,' Fesharaki-Zadeh said, adding that physical activity can boost neurogenesis (the formation of new neurons and synapses), vasculogenesis (the creation of new blood vessels) while also providing inherent mood benefits. Next, focus on eating nourishing foods. Fesharaki-Zadeh championed a Mediterranean-based diet, mentioning its well-documented benefits. 'Such dietary practice, which includes food groups such as green leafy vegetables, olive oil, salmon and blueberries, is rich in vitamins, omega-3 fatty acids, as well as antioxidants ― all neuroprotective factors,' he explained. Fesharaki-Zadeh recommended cognitive, mood and social stimulation to keep your mind sharp. For cognitive stimulation, this could look like learning a new language or attending a seminar, listening to music or dancing. Basically, anything that engages your mind will help it stay healthy. Mood stimulation, on the other hand, relates to stress reduction practices, 'such as mindfulness and yoga,' Fesharaki-Zadeh said. As for social stimulation, it's pretty simple: Try to connect with other humans face-to-face and actually talk to them as much as possible. 'In the era of pandemic and now post-pandemic, quality social connections should increasingly be encouraged and practiced,' Fesharaki-Zadeh said. While these habits don't cover the whole list of dementia risk factors, they are a pretty solid start. This article originally appeared on HuffPost.
Business Wire
3 hours ago
- Business Wire
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
BOSTON--(BUSINESS WIRE)--A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products. 'Johnson & Johnson knew its talc Baby Powder could kill, and they chose to keep selling it anyway, despite the availability of safer cornstarch-based powders,' said Ben Braly. 'We are grateful to the jury for holding them to account.' Share The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson & Johnson had internal knowledge of asbestos in its talc supply dating back decades yet continued to market the products as safe for daily use. J&J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi, a lifelong user of the company's Baby Powder on herself and her children, was diagnosed with mesothelioma in 2021. 'Johnson & Johnson knew its talc Baby Powder could kill, and they chose to keep selling it anyway, despite the availability of safer cornstarch-based powders,' said Ben Braly, one of Ms. Paluzzi's attorneys. 'We are grateful to the jury for holding them to account.' Ms. Paluzzi, 84, raised seven children in single-bathroom homes for 20 years. Today, she has 10 grandchildren and is suffering through her illness. The legal team included Ben Braly, Anthony Bianco and Aaron Chapman of Dean Omar Branham Shirley, along with Brian Kenney of Early, Lucarelli, Sweeney & Mesienkothen, LLC and Amy Carter with the Carter Law Group. 'Johnson & Johnson sold their product as safe and took advantage of the trust of families like Ms. Paluzzi's,' said Dean Omar Branham Shirley partner Trey Branham. 'She used it every day on herself and her children. The jury saw that betrayal and delivered justice.' The case is Janice Paluzzi v. Johnson & Johnson, Civil Action No. 21-2109, filed in Suffolk County Superior Court in Massachusetts. About Dean Omar Branham Shirley Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of irresponsible conduct of others. For more information, please visit
Business Wire
4 hours ago
- Business Wire
Veradigm to Release Business Update June 23 rd and Host Investor Call June 24 th
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Conference ID #13754301. A replay of the call will be available for a period of one year on the Veradigm investor relations website. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
